c-Kit
Les inhibiteurs de c-Kit sont des composés qui bloquent l'activité du Récepteur du Facteur de Cellules Souches (c-Kit), une tyrosine kinase jouant un rôle crucial dans la survie, la prolifération et la différenciation cellulaires, en particulier dans les cellules hématopoïétiques. Les mutations de c-Kit sont liées à divers cancers, notamment les tumeurs stromales gastro-intestinales (GIST) et la leucémie. Chez CymitQuimica, nous proposons des inhibiteurs de c-Kit pour soutenir vos recherches en oncologie, hématologie et biologie des cellules souches.
117 produits trouvés pour "c-Kit".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cabozantinib
CAS :Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).Formule :C28H24FN3O5Degré de pureté :99.82% - 99.89%Couleur et forme :SolidMasse moléculaire :501.51Flumatinib mesylate
CAS :Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.Formule :C30H33F3N8O4SDegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :658.69Ref: TM-T7861
1mg34,00€5mg84,00€1mL*10mM (DMSO)110,00€10mg126,00€25mg236,00€50mg371,00€100mg595,00€500mg1.234,00€Cabozantinib hydrochloride
CAS :Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formule :C28H25ClFN3O5Degré de pureté :99.97%Couleur et forme :White SolidMasse moléculaire :537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€Dovitinib
CAS :Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.Cost-effective and quality-assured.
Formule :C21H21FN6ODegré de pureté :99.35% - 99.92%Couleur et forme :SolidMasse moléculaire :392.43Sitravatinib
CAS :Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, andFormule :C33H29F2N5O4SDegré de pureté :98.9% - 99.85%Couleur et forme :SolidMasse moléculaire :629.68Ref: TM-T4349
5mg49,00€1mL*10mM (DMSO)69,00€10mg74,00€25mg130,00€50mg200,00€100mg319,00€200mg507,00€500mg800,00€Masitinib mesylate
CAS :Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;Formule :C29H34N6O4S2Degré de pureté :97.67% - 98.44%Couleur et forme :SolidMasse moléculaire :594.75c-Kit/CD117 Protein, Human, Recombinant (His & Avi), Biotinylated
The c-kit proto-oncogen (CD 117) has been shown to be present in several cell types including normal and neoplastic hemopoietic cells.Couleur et forme :White Lyophilized PowderMasse moléculaire :58.60 kDa (predicted). Due to glycosylation, the protein migrates to 75-105 kDa based on Tris-Bis PAGE result.Toceranib
CAS :Toceranib phosphate, orally active, inhibits RTK, PDGFR, VEGFR, Kit; Kis 5 nM PDGFRβ, 6 nM KDR; has antitumor effects.Formule :C22H25FN4O2Degré de pureté :97.62%Couleur et forme :SolidMasse moléculaire :396.46Barzolvolimab
CAS :Barzolvolimab (CDX 0159) is a humanized monoclonal antibody targeting KIT that reduces skin mast cells and disease activity in chronic inducible urticaria.Degré de pureté :95% - 95.6% (SDS-PAGE); 95.4% (SEC-HPLC)Couleur et forme :Transparent LiquidMasse moléculaire :144.63 kDaBriquilimab
CAS :Briquilimab is a humanized antibody that inhibits the SCF-KIT interaction, inducing mast cell apoptosis for research into inflammatory diseases.Degré de pureté :96.0% (SDS-PAGE); 96.0% (SEC-HPLC) - 96.0% (SDS-PAGE); 96.0% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.56 KDaAnti-Mouse CD117 Antibody
Anti-Mouse CD117 Antibody, a rat-derived IgG2b isotype, acts as an inhibitor specific to the mouse CD117 antigen.Degré de pureté :98%Couleur et forme :Odour LiquidEglatoprutug
CAS :Eglatoprutug is a humanized immunoglobulin G1-kappa monoclonal antibody targeting the c-Kit receptor [1].Couleur et forme :LiquidDovitinib Dilactic Acid
CAS :Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.Formule :C21H21FN6O·2C3H6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :572.59NN-2101
NN-2101 is a human monoclonal antibody (mAb) that targets c-Kit/CD117. It is applicable in research related to retinal diseases and diabetic macular edema.GW694590A
CAS :GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].Formule :C22H19N5O4Couleur et forme :SolidMasse moléculaire :417.42KI-328
CAS :KI-328: novel selective KIT kinase inhibitor; blocks Wt/mutant-KIT cell growth; low effect on D816V-KIT.Formule :C25H25N7O3Couleur et forme :SolidMasse moléculaire :471.51c-Kit-IN-3
CAS :c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).Formule :C26H20ClF3N2O4Degré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :516.9Ref: TM-T10651
1mg82,00€5mg154,00€10mg240,00€1mL*10mM (DMSO)316,00€25mg396,00€50mg532,00€100mg745,00€500mg1.494,00€KBP-7018
CAS :KBP-7018 is a selective TKI targeting c-KIT, RET, and PDGFR for mechanistic studies of fibrotic signaling and kinase-driven diseases.Formule :C31H30N4O5Degré de pureté :99.73%Couleur et forme :Yellow SolidMasse moléculaire :538.59Sitravatinib malate
CAS :Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5Formule :C37H35F2N5O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :763.76APcK110
CAS :"APcK110, a potent novel Kit inhibitor, outperforms imatinib/dasatinib in halting OCI/AML3 and HMC1.2 cell growth, also inhibiting Kit-signaling."Formule :C20H16FN3O2Couleur et forme :SolidMasse moléculaire :349.36
